Description:
Technology:
The
inventors have developed a biomarker application based on thromboxane receptor β
(TPβ), which identifies patients with various stages of bladder
cancers (invasive, superficial, or metastatic). TPβ
proteins are overexpressed in common bladder tumor tissue but not normal human
cells. Human urine samples of patients positive for various degrees of bladder
cancer confirm sensitivity approaching 93%, with 100% specificity. The detection
of these proteins
provide a novel, non-invasive early diagnostic method and for follow up
monitoring in case of recurrence.
Overview:
Bladder
cancer is the fifth
most common cancer in U.S. (4.6%).
When detected early stage, it has a 94% survival rate. Survival rate drops to 46% after
spreading to surrounding region, and declines to 6% after metastases. The gold
standard for diagnosing via cystoscopy, however this is invasive, costly and is
limited to interpretation bias. Other diagnostic assays, such as cyoscopy and
fluorescent in situ hybridization (FISH), have limited sensitivity (50-70%). Improved sensitivity and specificity for
bladder cancer would significantly increase patient survival. Also given a high
recurrence rate, an easy to administer follow up procedure would be an effective
clinical application in healthcare.
Advantages:
Highly specific and selective early detection and progressive
monitoring of bladder cancer
Key Words:
Bladder cancer, urine analysis, assay, specificity, selectivity,
diagnostic, thromboxane receptor
Inventors:
Omar Moussa, Dennis Watson, Perry
Halushka
Patent Status:
Issued U.S. Patent 8,101,371
MUSC-FRD Technology ID:
P0804